title: Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers.
abstract: A study was conducted to evaluate the therapeutic efficacy of bacteriophage and the antibiotic enrofloxacin individually and in combination to treat colibacillosis. The experimental design was a 2 x 2 x 2 factorial with 8 treatments and 4 replicate pens of 10 birds. The treatments were 1) control, 2) unchallenged birds treated with bacteriophage, 3) enrofloxacin, or 4) the combination; 5) birds challenged with Escherichia coli, and birds challenged with E. coli and treated with 6) bacteriophage, 7) enrofloxacin, or 8) the combination of bacteriophage and enrofloxacin. Birds in the E. coli challenged treatments were challenged at 7 d of age by injecting 10(4) cfu of E. coli into the thoracic air sac. The antibiotic treatment was initiated immediately after the birds were challenged and consisted of 50 ppm enrofloxacin in the drinking water for 7 consecutive days. The bacteriophage treatment consisted of a single intramuscular injection of 2 different bacteriophage (10(9) pfu) administered immediately after the E. coli challenge. Mortality in the birds challenged with E. coli and untreated was 68%, and the bacteriophage and enrofloxacin treatments significantly decreased mortality to 15 and 3%, respectively. There was total protection in birds that received both the bacteriophage and enrofloxacin representing a significant synergy. The decrease in mortality with enrofloxacin (3%) was significantly better than the decrease in mortality with bacteriophage (15%). Airsacculitis lesion scores and lesion incidence in surviving birds were significantly less in the enrofloxacin treatment compared with the bacteriophage treatment. Both bacteriophage and enrofloxacin provided effective treatments of colibacillosis, and the synergy between these 2 treatments suggests that bacteriophage combined with antibiotic treatment has significant value.
authors.affiliation: Poultry Production and Product Safety Research Unit, USDA, Agricultural Research Service, Poultry Science Center, University of Arkansas, Fayetteville, Arkansas 72701, USA. huff@uark.edu
authors.forename: W E
authors.initials: WE
authors.lastname: Huff
authors.forename: G R
authors.initials: GR
authors.lastname: Huff
authors.forename: N C
authors.initials: NC
authors.lastname: Rath
authors.forename: J M
authors.initials: JM
authors.lastname: Balog
authors.forename: A M
authors.initials: AM
authors.lastname: Donoghue
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001435:Bacteriophages; D002645:Chickens / Q000254:growth & development / Q000382:microbiology*; D003131:Combined Modality Therapy / Q000662:veterinary; D000077422:Enrofloxacin; D004927:Escherichia coli Infections / Q000628:therapy / Q000662:veterinary*; D024841:Fluoroquinolones / Q000627:therapeutic use*; D008297:Male; D011201:Poultry Diseases / Q000188:drug therapy / Q000382:microbiology / Q000628:therapy*; D015363:Quinolones / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D015363:Quinolones; D000077422:Enrofloxacin